BioNTech (BNTX) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for BioNTech (NASDAQ: BNTX):

• 4/27/2026 – BioNTech had its “buy” rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.
• 4/13/2026 – BioNTech had its “buy” rating reaffirmed by Berenberg Bank.
• 4/10/2026 – BioNTech had its price target raised by Morgan Stanley from $125.00 to $126.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – BioNTech had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 3/31/2026 – BioNTech had its price target lowered by HC Wainwright from $140.00 to $130.00. They now have a “buy” rating on the stock.
• 3/25/2026 – BioNTech was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/25/2026 – BioNTech had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 3/17/2026 – BioNTech had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft.
• 3/14/2026 – BioNTech was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/11/2026 – BioNTech had its “buy” rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
• 3/11/2026 – BioNTech had its price target lowered by Citigroup Inc. from $145.00 to $130.00. They now have a “buy” rating on the stock.
• 3/11/2026 – BioNTech had its price target lowered by TD Cowen from $116.00 to $94.00. They now have a “hold” rating on the stock.
• 3/11/2026 – BioNTech had its price target lowered by BMO Capital Markets from $143.00 to $128.00. They now have an “outperform” rating on the stock.
• 3/11/2026 – BioNTech had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 3/10/2026 – BioNTech was given a new $155.00 price target by Truist Financial Corporation.
• 3/10/2026 – BioNTech had its “outperform” rating reaffirmed by Raymond James Financial, Inc..
• 3/10/2026 – BioNTech had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $128.00 price target on the stock.
• 3/10/2026 – BioNTech had its price target lowered by Morgan Stanley from $134.00 to $125.00. They now have an “overweight” rating on the stock.
• 3/10/2026 – BioNTech had its price target lowered by Jefferies Financial Group Inc. from $151.00 to $138.00. They now have a “buy” rating on the stock.

Insider Transactions at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of BioNTech stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the sale, the chief operating officer directly owned 399,387 shares in the company, valued at approximately $44,156,226.72. The trade was a 11.13% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.